Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.
The user has been using a hair loss treatment regimen including RU58841, minoxidil, and dutasteride, but still experiences hairline recession and fatigue despite high testosterone levels. They are considering adjusting their dutasteride dosage due to concerns about libido and energy levels.
GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.
Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
The conversation is about adding a topical anti-androgen to a hair loss treatment regimen that includes dutasteride and oral minoxidil. The user is considering topical finasteride or dutasteride, Nizoral shampoo, KX-826, and topical spironolactone, while avoiding RU58841 due to safety concerns.
The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.
The user experienced significant hair regrowth using a combination of minoxidil, alfatradiol, pyrilutamide, and nizoral, despite previous intolerance to finasteride. They emphasize the importance of consistency in treatment and are optimistic about the results, noting no side effects so far.
Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.
The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.
Starting hair loss treatment early is crucial for better results. Dutasteride and finasteride are effective, with dutasteride often considered superior, while oral minoxidil shows better gains than topical.
The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.
A new hair loss treatment, Pyrilutamide, has been released and is claimed to be a strong anti-androgen, potentially effective when used with finasteride. However, there are mixed opinions on its effectiveness and safety, with some users skeptical and others purchasing it.
The user is using a topical dutasteride/minoxidil/tretinoin gel for hair thinning and has had a positive experience with no side effects. They also mention considering another product, Formula82D, after having decent results with Formula82F.
A 21-year-old male is using a topical treatment for hair loss, including Dutasteride, Minoxidil, Tretinoin, Ketoconazole, and Hydrocortisone, along with derma rolling. He reports no side effects from the treatment and seeks feedback on its effectiveness for hair regrowth.
The user has high free testosterone and is still experiencing hair loss despite taking dutasteride and oral minoxidil for over three years. They are considering adding a topical anti-androgen like RU58841.
A 29-year-old male shares his hair loss treatment progress using dutasteride, minoxidil, dermastamping, and ketoconazole shampoo, while discontinuing RU58841 due to side effects. He is hopeful for hair recovery to consider a hair transplant and discusses potential side effects and experiences with other users.
Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.
The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
The user experienced significant hair regrowth after 11 months using 0.5 mg dutasteride and 5 mg oral minoxidil daily, initially using a topical treatment with finasteride, minoxidil, and tretinoin. They reported no side effects, except for increased body hair and longer eyelashes, and switched from finasteride to dutasteride for more regrowth.
The user shared their successful hair regrowth experience using Dutas, oral and topical minoxidil, vitamin D3, zinc, biotin, a laser cap, natural shampoos, ketoconazole shampoo, retinoic acid lotion, and mesotherapy. They reported no side effects and significant improvement in hair thickness and color over six months.
The user has been using pyrilutamide 0.5% for over 7 weeks, alongside dutasteride, and noticed some hair improvement, particularly at the temples. They plan to continue and possibly try a 1% solution, with no shedding or side effects reported.
The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.